Forty Seven, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Palo Alto CA United States (2015)
Status: Acquired by Gilead Sciences (2020)

Organization Overview

First Clinical Trial
2015
NCT02216409
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Forty Seven Inc | Forty Seven, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Transitional Cell (Phase 2)

Colorectal Neoplasms (Phase 2)

Hematologic Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Ovarian Neoplasms (Phase 1)

Preleukemia (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 12